Arcutis Biotherapeutics, Inc.
ARQT
$13.01
$0.050.39%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 46.58% | 27.01% | 39.92% | 33.56% | 15.83% |
| Total Depreciation and Amortization | 70.87% | 70.33% | 7.47% | 32.17% | 62.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.90% | 7.30% | -40.07% | -41.14% | -41.15% |
| Change in Net Operating Assets | 35.83% | 58.17% | 11.64% | -6.29% | -130.97% |
| Cash from Operations | 54.60% | 35.98% | 38.04% | 29.45% | 4.14% |
| Capital Expenditure | 66.59% | 72.66% | 85.63% | -18.90% | -28.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -83.97% | -123.88% | -353.93% | 695.71% | 307.98% |
| Cash from Investing | -84.01% | -123.98% | -357.06% | 733.19% | 306.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 64.03% | 8,675.10% | 60.30% | 60.00% | -43.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -34.66% | 8,675.10% | -8.27% | -8.42% | -66.43% |
| Foreign Exchange rate Adjustments | -370.00% | 156.78% | -146.51% | -36.54% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -150.43% | 5.67% | -148.86% | 859.07% | 179.90% |